


AMENDMENTS

In the Claims

Claim 1 (previously presented): A compound of Formula (I):



(I)

wherein:

R¹ and R² are, independently of each other:

(i) hydrogen;

(ii) alkyl; or

(iii) -COR³ wherein R³ is selected from the group consisting of alkyl, amino,

monosubstituted amino, disubstituted amino, or alkyl substituted with one, two or three substituents selected from the group consisting of amino, monosubstituted amino, disubstituted amino, guanidino, amidino, aminoacyl, -NHCOR^a (wherein R^a is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), -NHCONHR^a (wherein R^a is as defined above), aryl, substituted aryl, heteroaryl, substituted heteroaryl, carboxy, alkoxycarbonyl, and -OR^b (where R^b is hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl), provided that at least one of R¹ and R² is a group that can form a pharmaceutically acceptable acid addition salt;

n and m are independently an integer from 0 to 4; and

Ar^1 , Ar^2 , Ar^3 , and Ar^4 are independently selected from the group consisting of arylene, substituted arylene, and optionally substituted heteroarylene; and

L is:

- (i) alkylene or cycloalkylene;
- (ii) alkylene substituted with one, two or three substituent(s) selected from the group consisting of aryl, $-\text{CONHR}^4$ (wherein R^4 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl, heterocyclic, substituted heterocyclic, heterocyclicalkyl, heteroarylthioalkyl, or $-(\text{CHR}^5)_{n1}-\text{CO}-(\text{NH}-\text{Ar}^3-\text{CO})_m-\text{NH}-\text{Ar}^4-\text{CO}-\text{NHR}^3$ where $n1$ is 1 to 3, R^5 is hydrogen or alkyl, substituted alkyl, and Ar^3 , m , Ar^4 , and R^3 are as defined above), $-\text{CONHNHR}^6$ [wherein R^6 is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, $-\text{COR}^7$, $-\text{COOR}^8$ (wherein R^7 and R^8 are independently of each other alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, cycloalkyl, substituted cycloalkyl, cycloalkylalkyl, substituted cycloalkylalkyl, heteroaryl, substituted heteroaryl, or heteroaralkyl), heteroaryl, or heteroaralkyl], $-\text{NHR}^9$ (wherein R^9 is hydrogen, alkyl, substituted alkyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, aminoalkylcarbonyl, or heterocycliccarbonyl), and guanidino; or
- (iii) $-(\text{alkylene})_x-\text{Z}-(\text{alkylene})_y-(\text{Z}^a)_z-$ wherein x , y and z are independently 0, 1, or 2 and Z and Z^a are, independently of each other, phenylene, cycloalkylene optionally fused to one or two phenylene ring(s), heterocyclene, $-\text{O}-$, $-\text{S}-$, $-\text{NR}^{10}-$ [wherein R^{10} is hydrogen, alkyl, substituted alkyl, cycloalkylcarbonyl, hydroxyalkyl, alkoxyalkyl, aminoalkyl, $-\text{CONHR}^4$, $-\text{COR}^7$, $-\text{COOR}^8$ (where R^4 , R^7 and R^8 are as defined above), $-\text{SO}_2\text{R}^{11}$ (where R^{11} is alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, substituted aralkyl, heteroaryl, substituted heteroaryl, heteroaralkyl, or substituted heteroaralkyl) or $-(\text{CHR}^5)_{n2}-\text{NH}-(\text{CO}-\text{Ar}^3-\text{NH})_m-\text{CO}-\text{Ar}^4-\text{NHR}^2$ where $n2$ is 2 to 4, R^5 is hydrogen, alkyl, or substituted alkyl, and Ar^3 , m , Ar^4 , and R^2 are as defined above], $-\text{CO}-\text{NH}-$, or $-\text{NH}-\text{CO}-$, provided that

when Z and/or Z^a is $-\text{NR}^{10}-$ then it is separated from another nitrogen atom by at least two carbon atoms;

or a pharmaceutically acceptable salt thereof.

Claim 2 (original): The compound of Claim 1 wherein Ar¹, Ar², Ar³ and Ar⁴ are independently an optionally substituted heteroaryl.

Claim 3 (original): The compound of Claim 2 wherein Ar¹, Ar², Ar³ and Ar⁴ are independently a 1-methylpyrrole that is linked to the carbonyl group at the 2-position and the amino group at the 4-position of the pyrrole ring.

Claim 4 (original): The compound of Claim 1 wherein n and m are 0 or 1.

Claim 5 (original): The compound of Claim 4 wherein Ar¹, Ar², Ar³ and Ar⁴ are independently an optionally substituted heteroaryl.

Claim 6 (original): The compound of Claim 1 wherein R¹ and R² are independently -COR³.

Claim 7 (original): The compound of Claim 6 wherein R¹ and R² are independently aminomethylcarbonyl, 1-amino-4-guanidinobutylcarbonyl, 1,4-diaminobutylcarbonyl, 1,5-diaminopentyl-carbonyl, 1-amino-5-(3,4difluorophenylureido)pentylcarbonyl, 1-(3,4-difluorophenylureido)-4-guanidinobutylcarbonyl, 1-[4-(N,N-(2-chloroethyl)-aminophenylbutanoyl)]amino-4-guanidinobutylcarbonyl, 1-amino-5-[4-(N,N-(2-chloroethyl)-aminophenylbutanoyl)]aminopentylcarbonyl, or pyrene-1-ylmethoxy.

Claim 8 (original): The compound of Claim 1 wherein L is alkylene.

Claim 9 (original): The compound of Claim 8 wherein L is 1,2-ethylene, 1,3-propylene, 1,4-butylene, 1,6-hexylene, 1,8-octylene, 1,12-dodecylene, 1-methylethylene, or 1,2-hexadecylene.

Claim 10 (original): The compound of Claim 1 wherein L is substituted alkylene.

Claim 11 (original): The compound of Claim 10 wherein L is meso-1,2-diphenylethylene, 1-(p-nitrophenylaminocarbonyl)-1,5-pentylene, 1-(naph-2-ylaminocarbonyl)-1,5-pentylene,

1-(pentafluorophenylhydrazidocarbonyl)-1,5-pentylene, 1-(5-trifluoro-pyrimidin-2-ylhydrazidocarbonyl)-1,5-pentylene, 1-(2-pyrene-lylethylamino-carbonyl)-1,5-pentylene, 1-[2-(6-nitrobenzimidazol-1-ylethylaminocarbonyl)]-1,5-pentylene, 1-[2-(indol-3-yl)-ethylaminocarbonyl]-1,5-pentylene, 1-[2-(5-fluoroindol-3-yl)ethylaminocarbonyl]-1,5-pentylene, 1-[2-(4-nitrophenyl)ethylaminocarbonyl]-1,5-pentylene, 1-(benzyloxycarbonyl-hydrazidocarbonyl)-1,2-ethylene, 1-(naphth-1-ylaminocarbonyl)-1,5-pentylene, 1-(4-pyrene-1-ylbutylaminocarbonyl)-1,5-pentylene, 1-(2-(2-trifluoromethylquinolin-4-yl)thio-ethylaminocarbonyl)-1,5-pentylene, 1-(pentafluorophenylhydrazidocarbonyl)-1,4-butylene, 1-(4-pyrene-1-ylmethylaminocarbonyl)-1,5-pentylene, 1-(2-hydroxyethylaminocarbonyl)-1,5-pentylene, 1-(2-aminoethylaminocarbonyl)-1,5-pentylene, 1-(3-dimethylaminopropyl-aminocarbonyl)-1,5-pentylene, 1-(bis-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 1-(N-(2-aminoethyl)aminoethylaminocarbonyl)-1,5-pentylene, 2-(aminomethylcarbonyl-amino)-1,3-propylene, or 2-(3-hydroxypyrrolidin-5-ylcarbonyl-amino)-1,3-propylene.

Claim 12 (original): The compound of Claim 1 wherein L is $-(\text{alkylene})_x\text{-Z-(alkylene)}_y\text{-(Z}^a\text{)}_z\text{-}$.


Claim 13 (original): The compound of Claim 12 wherein L is m-xylene, p-xylene, 2,7-fluorendiyl, *bis*-(3-N-benzyloxycarbonylamino)propylene $[-(\text{CH}_2)_3\text{-N(BzOCO)-}(\text{CH}_2)_3\text{-}]$, *bis*-(2-naphth-2-ylsulfonylamino)ethylene $[-(\text{CH}_2)_2\text{-N(-SO}_2\text{naphth-2-yl)-}(\text{CH}_2)_2\text{-}]$, *bis*-(2-N-3,5-dinitrophenylcarbonylamino)ethylene $[-(\text{CH}_2)_2\text{-N(-CO-3,5-dinitrophenyl)-}(\text{CH}_2)_2\text{-}]$, 1,3-cyclohexyl-bis-methylene $[-(\text{CH}_2)\text{-(1,3-C}_6\text{H}_{10}\text{)-}(\text{CH}_2)\text{-}]$, 1,4-cyclohexyl-bis-methylene $[-(\text{CH}_2)\text{-(1,4-C}_6\text{H}_{10}\text{)-}(\text{CH}_2)\text{-}]$, 4,4'-methylene-bis-1,4-cyclohexylene $[-(1,4\text{-C}_6\text{H}_{10})\text{-(CH}_2\text{)-(1,4-C}_6\text{H}_{10}\text{)-}]$, 1,2-cyclohexylene (1,2-C₆H₁₀-), *bis*-(2-adamantyl-ylcarbonylamino)ethylene, *bis*-(3-N-methylamino)propylene $[-(\text{CH}_2)_3\text{-N(-CH}_3\text{)-}(\text{CH}_2)_3\text{-}]$, *bis*-(3-amino)propylene $[-(\text{CH}_2)_3\text{-NH-(CH}_2)_3\text{-}]$, 1,4-piperazino- *bis*-propylene $[-(\text{CH}_2)_3\text{-(1,4-piperazino)-}(\text{CH}_2)_3\text{-}]$, *bis*-(2-(2-aminoethyl)amino)ethylene $[-(\text{CH}_2)_2\text{-N(-}(\text{CH}_2)_2\text{NH}_2\text{)-}(\text{CH}_2)_2\text{-}]$, and *bis*-(2-amino)ethylene $[-(\text{CH}_2)_2\text{-NH-(CH}_2)_2\text{-}]$.

Claim 14 (original): A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claims 1-13 and a pharmaceutically suitable carrier.

Claim 15 (currently amended): A method for the treatment of diseases caused by pathogenic organisms wherein said organisms are selected from the group consisting of bacteria, fungi and parasites which method comprises administering to a mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition containing a therapeutically effective amount of a compound of Claims 1-13 and a pharmaceutically suitable carrier.

Claim 16 (original): The method of Claim 15 wherein the disease is cancer.





Claim 17 (withdrawn): A compound of the formula (II).











wherein R^{21} is an arylene, heteroarylene, substituted arylene or substituted heteroarylene; each R^{20} is independently alkyl or substituted alkyl; and each R^{22} is independently guanidino or amidino.

Claim 18 (withdrawn): The compound of claim 17 where in R^{21} is selected from the group consisting of 1,4-phenylene, 1,3-phenylene, 1,3-pyridylene, 1,4-pyridylene, 2,4-pyrimidinylene, 2,5-pyrimidinylene, 3,5-(1,2,4)-triazolene, 2,5-thiazolene, and 2,7-naphthylene; wherein said 1,4-phenylene and 1,3-phenylene are optionally substituted; and each R^{20} is independently selected from the group consisting of methyl, ethyl, propyl, isoamyl, and cyclopropylmethyl.

Claim 19 (withdrawn): The compound of claim 18 selected from the group consisting of








and pharmaceutically acceptable salts thereof.

Claim 20 (previously presented): A compound of claim 1 which compound is represented by formula (VII)





wherein


L is selected from the group consisting of alkylene and cycloalkylene;

A is an amino acid side chain; and


R²³ is selected from the group consisting of guanidino, amino, and ornithylamino.

Claim 21 (original): A compound of claim 20 selected from the group consisting of







173




169



171



170



172

and pharmaceutically acceptable salts thereof.

Claim 22 (withdrawn): A compound selected from the group consisting of:

Compounds 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 63, 66, 67, 68, 69, 70, 71, 72, 73, 74, 76, 77, 78, 79, 80, 81, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158. (depicted on pages 17-25, and Figures 1-8).